NCT01667926.

Study name	Randomized, double‐blind ketamine augmentation in chronically suicidal, treatment‐resistant major depression
Methods	Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients
Participants	Inclusion criteria Outpatient with sever treatment resistant depression Currently depressed Currently under regular psychiatric care On an aggressive antidepressant regimen, stable for 4 weeks. Exclusion criteria No history of other major psychiatric illness, including bipolar No history of psychosis No history of drug abuse No major medical illness or unstable medical problem
Interventions	Ketamine/saline 6 infusions of ketamine over three weeks
Outcomes	Primary outcome measures: HRSD‐28. Time frame: up to 4 months. [Designated as safety issue: No]. Participants will be assessed with HAM‐D
Starting date	January 2013
Contact information	Cristina Cusin, M.D., MGH Department of Psychiatry
Notes